Troriluzole in Adult Participants With Spinocerebellar Ataxia

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

299

Participants

Timeline

Start Date

March 8, 2019

Primary Completion Date

February 18, 2022

Study Completion Date

October 31, 2025

Conditions
Spinocerebellar AtaxiasSpinocerebellar Ataxia Type 1Spinocerebellar Ataxia Type 2Spinocerebellar Ataxia Type 3Spinocerebellar Ataxia Type 6Spinocerebellar Ataxia Type 7Spinocerebellar Ataxia Type 8Spinocerebellar Ataxia Type 10
Interventions
DRUG

troriluzole

Administered orally

DRUG

Placebo

Administered orally

Trial Locations (23)

10032

Columbia University, New York

19107

University of Pennsylvania, Philadelphia

21093

Johns Hopkins Medicine, Lutherville

27705

Duke University Movement Disorders Clinic, Durham

30329

Emory, Atlanta

32224

Mayo Clinic Florida, Jacksonville

32610

University of Florida Health, Gainesville

33612

University of South Florida, Tampa

48109

University of Michigan, Ann Arbor

60008

Northwest Neurology, Ltd., Rolling Meadows

60611

Northwestern University, Chicago

60637

University of Chicago, Chicago

77030

Houston Methodist, Houston

80045

University of Colorado Hospital, Aurora

85013

Barrow Neurological Institute, Phoenix

90095

UCLA, Los Angeles

90806

CNS Trials, Long Beach

94158

UCSF, San Francisco

98122

Swedish Health Services, Seattle

410008

Central South University Xiangya Hospital, Changsha

610041

West China Hospital of Sichuan University, Chengdu

02114

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors
All Listed Sponsors
lead

Biohaven Pharmaceuticals, Inc.

INDUSTRY